Baseline circulating tumor DNA (ctDNA) biomarker analysis of patients with human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic non-small cell lung cancer (NSCLC) treated with trastuzumab deruxtecan (T-DXd)

被引：0
|
作者：
Smit, E. F. [1 ]
Felip, E. [2 ]
Uprety, D. [3 ]
Nagasaka, M. [4 ]
Nakagawa, K. [5 ]
Paz-Ares, L. [6 ]
Pacheco, J. [7 ]
Li, B. T. [8 ]
Planchard, D. [9 ]
Baik, C. S. [10 ]
Goto, Y. [11 ]
Murakami, H. [12 ]
Pereira, K. M. C. [13 ]
Taguchi, A. [14 ]
Kogo, M. [14 ]
Kuwahara, Y. [13 ]
Zou, M. [13 ]
Feng, W. [13 ]
Tsuchihashi, Z. [13 ]
Janne, P. A. [15 ]
机构：
[1] Univ Med Ctr, Dept Pulm Dis, Leiden, Netherlands
[2] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[3] Barbara Ann Karmanos Canc Inst, Med Oncol, Detroit, MI USA
[4] Univ Calif Irvine, Sch Med, Med, Orange, CA USA
[5] Kindai Univ Hosp, Med Oncol, Osaka, Japan
[6] Clin Univ Navarra, Med Oncol, Madrid, Spain
[7] Univ Colorado, Ctr Canc, Internal Med, Med Oncol, Aurora, IL USA
[8] Mem Sloan Kettering Canc Ctr, Med, New York, NY USA
[9] Gustave Roussy, Med Oncol, Villejuif, France
[10] Univ Washington, Med Oncol, Seattle, WA USA
[11] Natl Canc Ctr, Thorac Oncol Dept, Tokyo, Japan
[12] Shizuoka Canc Ctr, Med Oncol, Shizuoka, Japan
[13] Daiichi Sankyo Inc, Oncol, Basking Ridge, NJ USA
[14] Daiichi Sankyo Co Ltd, Oncol, Tokyo, Japan
[15] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2875
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
151P
引用
收藏
页码：S241 / S242
页数：2
相关论文
共 50 条
  • [41] A phase 2, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select human epidermal growth factor receptor 2 (HER2)-expressing solid tumors (DESTINY-PanTumor02)
    Meric-Bernstam, Funda
    Anoka, Chiedozie
    Dobrowolska, Anna
    Chaudhry, Anubhavini
    Rowbottom, Jacqui
    Gustavson, Mark
    Puvvada, Soham
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S156 - S156
  • [42] Exploring the prevalence and characteristics of human epidermal growth factor receptor 2 (HER2) alterations in non-small cell lung cancer: Analysis from a Malaysian cohort
    Yap, N. Y.
    Perumal, K.
    Rajadurai, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S1699 - S1700
  • [43] A phase 2, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select human epidermal growth factor receptor 2 (HER2)-expressing solid tumors (DESTINY-PanTumor02)
    Meric-Bernstam, Funda
    Anoka, Chiedozie
    Dobrowolska, Anna
    Chaudhry, Anubhavini
    Rowbottom, Jacqui
    Gustavson, Mark
    Puvvada, Soham D.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [44] Epidermal Growth Factor Receptor (EGFR) and HER2 gene amplification predict response to gefitinib therapy in advanced non-small cell lung cancer (NSCLC)
    Cappuzzo, Federico
    Hirsch, Fred R.
    Rossi, Elisa
    Bartolini, Stefania
    Ceresoli, Giovanni-Luca
    Ludovini, Vienna
    Franklin, Wilbur A.
    Crino, Lucio
    Bunn, Paul A.
    Varella-Garcia, Marileila
    ANNALS OF ONCOLOGY, 2004, 15 : 166 - 166
  • [45] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic nonesmall cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02
    Li, B. T.
    Planchard, D.
    Goto, K.
    Smit, E. F.
    De langen, J.
    Goto, Y.
    Ninomiya, K.
    Kubo, T.
    Perol, M.
    Felip, E.
    Hayashi, H.
    Nakagawa, K.
    Shimizu, J.
    Nagasaka, M.
    Pereira, K. M. C.
    Taguchi, A.
    Ali, A.
    Karnoub, M.
    Yonemochi, R.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2023, 34
  • [46] A Review of Epidermal Growth Factor Receptor/HER2 Inhibitors in the Treatment of Patients With Non-Small-Cell Lung Cancer
    Govindan, Ramaswamy
    CLINICAL LUNG CANCER, 2010, 11 (01) : 8 - 12
  • [47] Changes in Circulating Epidermal Growth Factor Receptor (EGFR) during Radiotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients
    Ye, Ping
    Zhao, Jing
    Maihle, Nita
    Wang, Shulian
    Jin, Jianyue
    Kong, Feng-Ming
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S605 - S605
  • [48] Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer
    Gouda, Mohamed A.
    Gonugunta, Amrit
    Dumbrava, Ecaterina E.
    Yap, Timothy A.
    Rodon, Jordi
    Piha-Paul, Sarina A.
    Pohlmann, Paula R.
    Damodaran, Senthil
    Murthy, Rashmi
    Valero, Vicente
    Mouabbi, Jason A.
    Tripathy, Debasish
    Sahin, Aysegul A.
    Chen, Hui
    Meric-Bernstam, Funda
    CLINICAL CANCER RESEARCH, 2025, 31 (07) : 1268 - 1274
  • [49] Open-label, multinational, multicenter, phase IIIb/IV study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with previously treated advanced/metastatic human epidermal growth factor receptor 2epositive breast cancer (HER2+BC): DESTINY-Breast12
    Lin, N. U.
    Ciruelos, E.
    Jerusalem, G.
    Mueller, V.
    Niikura, N.
    Viale, G.
    Oscroft, E.
    Anand, S.
    Walker, G.
    Harbeck, N.
    ANNALS OF ONCOLOGY, 2021, 32 : S512 - S513
  • [50] Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer: Primary Results of DESTINY-Lung02
    Janne, P.
    Goto, Y.
    Kubo, T.
    Ninomiya, K.
    Kim, S. -W.
    Planchard, D.
    Ahn, M. -J.
    Smit, E. F.
    de Langen, A. J.
    Perol, M.
    Pons-Tostivint, E.
    Novello, S.
    Hayashi, H.
    Shimizu, J.
    Kim, D. -W.
    Pereira, K.
    Cheng, F. -C.
    Taguchi, A.
    Cheng, Y.
    Goto, K.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S148 - S148
12345